ArticleClinical rheumatology2025
Association between systemic lupus erythematosus and cardiovascular health based on genetic data.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the genetic causal relationship between systemic lupus erythematosus (SLE) and cardiovascular diseases through Mendelian randomization (MR) analysis.
methodsThis study employed a two-sample bidirectional MR design. Data were sourced from publicly available genome-wide association study (GWAS) databases. A total of 482,911 European individuals diagnosed with SLE were selected, covering 24,198,877 single-nucleotide polymorphisms (SNPs), along with relevant GWAS summary data for cardiovascular diseases. Genetic variants were used as instrumental variables. The MR analysis was conducted using the TwoSampleMR R package, employing methods including inverse-variance weighting (IVW), weighted median, and MR-Egger to assess the causal relationships. Sensitivity analyses were also performed to verify result robustness.
resultsMR analysis indicated potential causal risk relationships between genetic predisposition to SLE and increased risk of pericarditis and peripheral artery disease (PAD). Conversely, reverse MR analyses did not demonstrate significant causal associations, with IVW estimates indicating no causal relationships between coronary artery disease (OR = 1.038, 95%CI 0.829-1.3, P = 0.745), dilated cardiomyopathy (OR = 1.044, 95%CI 0.907-1.203, P = 0.548), heart failure (OR = 0.991, 95%CI 0.729-1.348, P = 0.956), hypertrophic cardiomyopathy (OR = 0.958, 95%CI 0.896-1.024, P = 0.207), pericarditis (OR = 0.958, 95%CI 0.821-1.118, P = 0.589), or PAD (OR = 1.157, 95%CI 0.625-2.143, P = 0.642) and the risk of SLE.
conclusionsThis study utilizes MR analysis to reveal genetic causal relationships between SLE and cardiovascular complications, specifically pericarditis and PAD. These findings suggest that inflammation control in SLE patients may help prevent pericarditis while managing dyslipidemia could mitigate PAD risk. Key Points • This study utilizes MR analysis to reveal the causal relationships between SLE and conditions such as pericarditis and PAD from a genetic perspective. • It suggests that controlling inflammation in the treatment of SLE can prevent pericarditis, and managing abnormal lipid levels can reduce the risk of PAD.
Indexed as
Identifiers
40317457What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.